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The project was conducted to evaluate the effect of lead administered as lead acetate at different 
dosage levels via drinking water in broiler chicks. Thirty-five healthy chicks were divided into seven 
groups (five chicks each) and one group was kept as un-medicated control. Groups A, B, C, D, E and F 
were medicated with lead acetate in a single dose at a rate of 80, 120, 160, 200, 240 and 280 mg/kg of 
body weight respectively for twenty five days consecutively. Various biochemical parameters, that is, 
glutamate pyruvate transaminase, creatinine and uric acid were determined by using 
spectrophotometer. A significant (P<0.05) increase was recorded in GPT, creatinine and uric acid levels 
in all medicated groups. The GPT, creatinine and uric acid levels were significantly (P<0.05) higher in 
groups medicated with high doses of 240 and 280 mg/kg b.wt of lead acetate. Analysis of variance 
showed that the DATA were significant not only from the single factor (dose/days) point of view, but 
also from their combined effect (dose rate × different days of analysis), which gave significant results 
with a P value less than 0.05. The mortality rate of 20% was observed for the groups medicated with 
120, 160 and 200 mg/kg b.wt, while 60% was observed for the groups medicated with 240 and 280 mg/kg 
b.wt. Postmortem revealed gross lesions on liver, lungs, kidney and brain at high doses of lead acetate. 
The lead was also accumulated in different organs, such as, the bone (14.83 ± 0.18 µg/g), brain (2.63 ± 
0.16 µg/g) and liver (1.05 ± 0.16 µg/g). These results showed that lead possessed significant capability 
of bioaccumulation. However, it also revealed that lead toxicity increased as the dose increased and 
high dose of lead caused both hepatotoxicity and nephrotoxicity in broiler chickens. 
 





Raising poultry in Pakistan has virtually proven to be a 
profitable enterprise, as it is the best source of cheap, 
palatable and nutritious food protein. The shortage of 
animal protein in Pakistan is estimated at 0.93 million 
tons on the basis of a human population of 140 million. 
This shortage of protein can be well managed with 
increase in the production of poultry meat at a reasonable 
cost (Alam et al., 2007). The conditions which arouse 
suspicion of poisoning are illnesses in a number of pre-
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the same signs and necropsy findings at the same 
degree of severity. The appearance of clinical illness, 
soon after feeding and after a change of ration, medica-
tion or spraying, or after a change to new posture, is a 
common history in many outbreaks of diseases caused 
by chemical agents. Poisoning is, in most instances, 
accidental, although it may occasionally be deliberate. 
The cause of lead poisoning is the accidental ingestion of 
sources of lead compounds or the ingestion of animal 
feed (Radostitis et al., 1994). 
Heavy metals become toxic when they are not metabo-
lized by the body and accumulated in the soft tissues. 
Heavy metals may enter the human body through food, 
water, air, or absorption through the skin when they come 
in contact with humans in agriculture  and  in  manufacturing, 




pharmaceutical, industrial, or residential settings 
(Radostitis et al., 1994). Lead acetate is a chemical 
compound, that is, a white crystalline substance having 
slight acetic acid odor with a sweetish taste. Like other 
lead compounds, it is very toxic. Lead acetate is soluble 
in water and glycerin. In low concentration, it is the 
principal active ingredient in progressive types of hair 
coloring dyes. Lead acetate is also used as a mordant in 
textile printing and dyeing, as a drier in paints and 
varnishes, and in preparing other lead compounds 
(Seacole, 1990). The common sources of lead in animals 
are lead bearing paints. There is a considerable variation 
between species in their susceptibility to lead and the 
chemical composition of the compound containing lead, 
which may influence its toxicity. The toxicity also varies 
with the chemical form of the lead. Lead acetate is very 
soluble and more toxic than insoluble lead oxides, or 
solid lead sheeting (Radostitis et al., 1994). 
Birds can be exposed to lead via air, water, food, lead 
batteries, paints, pestiside and gasoline. Previous 
researchers have found trends of decreasing net brain 
weight with increasing amount of lead in birds (Park et 
al., 2001). The lesions, including degeneration of liver 
and kidney, vary in their severity with the tissue levels of 
lead attained (Radostitis et al., 1994). Serum glutamate 
pyruvate transaminase (SGPT) is also known as 
alanineamino transferase (ALT), an enzyme produced in 
hepatocytes, the major cell type in the liver. ALT is often 
referred to as a liver function test; however, its level in the 
blood indicates little about the function of the liver. The 
level of ALT in the blood is increased in conditions in 
which hepatocytes are damaged or are dead. As cells are 
damaged, ALT leaks out into the bloodstream. The ALT 
level is also increased in cases of liver cell death 
resulting from other causes, such as shock or drug 
toxicity (Jaeger and Hedegard, 2002). Exposure to lead 
acetate can cause adverse effects on the kidneys, ureter 
or bladder. The kidney is unusually susceptible because 
of its role in filtering harmful substances from the blood. 
Some of the toxicants such as lead and cadmium 
cause acute injury to the kidney, while others produce 
chronic changes that can lead to end-stage renal failure 
or cancer (Amdur and Doull, 1996). Uric acid is made in 
the liver and excreted by the kidney. Uric acid is a waste 
product that results from the break down of purine (a 
nucleic acid). If the liver produces too much uric acid, the 
patient will have too much of it in the blood (Janis, 2002). 
Creatinine is a breakdown product of creatine, which is 
an important molecule of the muscle. Moreover, a serum 
creatinine test measures the amount of creatinine in the 
blood. The test is performed to evaluate the kidney’s 
function. If the kidney function is abnormal, creatinine 
levels will increase in the blood, due to decreased 
excretion of creatinine in the urine (Nissl and Terra, 2004; 
Hecht, 2006). 
Lead does not remain in tissues for long periods, 





from which it can be liberated at a later date in sufficient 








Day old broiler chicks were used as an experimental animal, 
purchased from the local market. A total of fifty chicks were kept 
under observation for twenty-one days in the Biopark of 
Biotechnology Department, University of Malakand with the 
purpose of selecting three weeks old healthy chicks. Same feed 
and water was provided to all the chicks during rearing, and it was 
seen that no antibiotic therapy was done during the experiment. 




Heavy metal used 
 
Lead acetate [(CH3 COO) 2 Pb.3H2O] (Merck Germany) and heparin 
injection (Rotex Medical Trittau, Germany) were used in this study. 





Grouping of broiler chicks 
 
After rearing the chicks for twenty-one days, thirty-five chicks were 
divided into seven groups (A, B, C, D, E, F and G) on the basis of 





Groups A, B, C, D, E and F were treated once a day with lead 
acetate at a dose rate of 80, 120, 160, 200, 240 and 280 mg/kg 
body weight, respectively. The medication was done via oral route 





Strict aseptic conditions were used during the blood sampling. The 
blood samples of 3 ml were collected from the wing vein of chicks 
for conduction of various biochemical tests. The blood samples 
were collected at 0 day before medication and at the 5th, 15th and 
25th day during medication, while at the 5th day of post medication, 
GPT, creatinine and uric acid were determined. 
 
 
Isolation of plasma 
 
The blood samples were centrifuged at 4000 rpm for 5 min. Plasma 
was separated and was used for the analysis of biochemical tests. 






Shimadzu UV-visible double beam spectrophotometer 1700 
Pharma   (Japan)  was  used  for  analysis  of  different  biochemical  




Table 1. The mean ± SD of GPT (iu/l) of the medicated and control groups of broiler chicks. 
 
Groups Dose rate (mg/kg- b. wt) 0 day (mg/dl) 5th day (mg/dl) 15th day (mg/dl) 25th (mg/dl) 30th day* (mg/dl) 
A 80 1.29 ± 0.008 1.38 ± 0.010 1.57 ± 0.024 1.59 ± 0.033 1.47 ± 0.091 
B 120 1.29 ± 0.008 1.51 ± 0.010 1.82 ± 0.048 1.99 ± 0.048 1.88 ± 0.072 
C 160 1.28 ± 0.019 2.64 ± 0.017 2.83 ± 0.028 2.94 ± 0.091 2.11 ± 0.039 
D 200 1.28 ± 0.017 2.52 ± 0.025 2.65 ± 0.015 2.84 ± 0.036 2.06 ± 0.029 
E 240 1.29 ± 0.010 2.35 ± 0.070 2.54 ±  0.080 2.70 ± 0.079 2.03 ±  0.014 
F 280 1.29 ± 0.008 2.06 ± 0.036 2.55 ± 0.049 2.59 ± 0.030 2.00 ± 0.024 
G Control 1.29 ± 0.008 1.28 ± 0.052 1.28 ± 0.033 1.26 ± 0.092 1.26 ± 0.025 
 




parameters, using plasma. Muffle furnace and atomic absorption 
spectrophotometer were used for ash preparation and for 






The following biochemical parameters were recorded to evaluate 




Estimation of glutamate pyruvate transaminase (GPT) 
 
The Crescent diagnostic kits (Saudi Arabia) were used for 
estimation of serum glutamate pyruvate transaminase (SGPT) by 
following the procedure given in the kit protocol. 
 
 
Estimation of creatinine 
 
Creatinine was estimated by the Kinetic method, without 
deproteinisation-Jaffe reaction, using Crescent diagnostics kits 
prepared by Saudi Arabia. 
 
 
Estimation of uric acid 
 
Uric acid was estimated by enzymatic colourimetric test using 
human diagnostic kit (Germany) according to the procedure given 





The post-mortems of dead broiler chicks were performed to study 
the gross pathological findings of the internal organs (liver, gizzard, 
heart, kidney and brain). 
 
 
Lead concentration in tissue 
 
The concentration of lead was determined in various tissues by 





The collected data were analyzed by two-way ANOVA for 
determination of variation among the effects of different dosage 
levels during different days. The mean, standard deviation (SD) and 
standard error from the mean (SEM) were also evaluated for each 
parameter, using Graph Pad Prism (Online software: 





Analysis of biochemical parameters 
 
The study of the following biochemical parameters was 
undertaken in this research. 
 
1. Glutamate pyruvate transaminase (GPT) 
2. Creatinine 
3. Uric acid 
 
 
Glutamate pyruvate transaminase (GPT) 
 
The GPT level of all groups was analyzed at 0 day before 
treatment, at 5, 15 and 25th day during medication, and 
at the 30th day of experiment after treatment. The mean 
± SD of the obtained values of GPT for all the groups 
have been shown in Table 2. For the un-medicated 
control group (G), the maximum value of GPT was 10.62 
± 0.010 IU/l and the minimum was 10.61 ± 0.008 IU /l. 
The uppermost level of GPT for Group A was 23.56 ± 
0.008 at the 25th day of experiment, while the lowest 
level was 18.33 ± 0.010 at the 5th day of experiment. The 
maximum level of GPT (48.28 ± 0.010 IU /l) for Group B 
was recorded at the 25th day of experiment, while the 
minimum level (35.24 ± 0.013 IU/l) was recorded at the 
5th day of the experiment (Table 1). The highest mean ± 
SD level of GPT for Group C was 65.12 ± 0.010 IU/l at 
the 25th day of the experiment, while the lowest was 
48.42 ± 0.010 at the 5th day of the experiment. Similarly, 
Group D showed high (58.56 ± 0.006 IU/l) and low level 
(45.31 ± 0.013 IU/l) levels of GPT at the 25th and 5th day 
of the experiment, respectively. The GPT level of Group 
E was high (51.84 ± 0.026 IU/l) at the 25th day and low 
(43.66 ± 0.006 IU/l) at the 5th day of the experiment. For 
Group F, the maximum GPT level of 45.06 ± 0.022 IU/l 
was recorded on day 25 and the  minimum  GPT  level  of   




Table 2. The mean ± SD of creatinine (mg/dl) of the medicated and control groups of broiler chicks. 
 
Group Dose rate 0 day (IU/l) 5th day (IU/l) 15th day (IU/l) 25th (IU/l) 30th day* (IU/l) 
A 80 10.61 ± 0.013 18.33 ±0.010 20.25 ±0.010 23.56 ± 0.008 22.12 ± 0.014 
B 120 10.61 ± 0.010 35.24 ±0.013 38.31 ±0.014 48.28 ± 0.010 44.31 ± 0.012 
C 160 10.62 ± 0.010 48.42 ±0.010 58.23 ±0.006 65.12 ± 0.010 59.28 ± 0.010 
D 200 10.61 ± 0.005 45.31 ±0.013 48.31 ±0.010 58.56 ± 0.006 49.31 ± 0.013 
E 240 10.61 ± 0.005 43.66 ±0.006 44.75 ±0.025 51.84 ± 0.026 48.28 ± 0.013 
F 280 10.55 ± 0.126 42.41 ±0.005 43.26 ±0.008 45.06 ± 0.022 43.09 ± 0.008 
G Control 10.61 ± 0.008 10.61 ±0.005 10.61 ±0.006 10.62 ± 0.010 10.62 ± 0.008 
 




42.41 ± 0.005 IU/l was recorded on day 5 of the 
experiment. 
The present study showed that lead acetate has an 
adverse effect on the liver and thus increased the level of 
GPT. As the dose increased, the GPT level also 
increased. At a dose rate of 80 mg/kg of b.wt (Group A), 
the GPT level was low and at a dose rate of 260 mg/kg of 
b.wt (Group E), the GPT level was high. Group C was 
highly affected than others, so their dose rate was low as 
compared to others (for example D, E and F). It was 
observed that as the administration was stopped, the 
GPT level tended towards normal as recorded on the 
30th day of the experiment for each group. Analysis of 
variance (ANOVA) of GPT level for all groups has been 
shown in Table 4. Table 4 showed that there was 
significant difference (P<0.05) in GPT level in different 
groups and also at different days of analysis. Their 
combined effect (dose rate × different days of analysis) 
was significant with a P value less than 0.05. 
A graph has been plotted between mean GPT level and 





The creatinine level for all non-medicated and medicated 
groups was recorded at 0 day before medication, at 5, 15 
and 25th
 
day during medication, and at the 30th day of 
the experiment (5th day of post medication). The mean ± 
SD of the obtained values is shown in Table 4. For Group 
G, which was kept as the un-medicated control, the 
minimum creatinine level was 1.26 ± 0.025 mg/dl and the 
maximum was 1.28 ± 0.033 mg/dl. Group A showed low 
level of creatinine (1.38 ± 0.010 mg/dl) observed on day 5 
and high level (1.59 ± 0.033 mg/dl) of creatinine observed 
on day 25 of the experiment. Similarly, the minimum level 
of creatinine (1.51 ± 0.010 mg/dl) for Group B was 
recorded at the 25th day of the experiment and the 
maximum (1.99 ± 0.048 mg/dl) was at the 5th day of the 
experiment (Table 2). The lowest mean ± SD level of 
creatinine for Group C was 2.64 ± 0.017 mg/dl, while the 
highest was 2.94 ± 0.091 mg/dl, and they were recorded 
on the 5th and 25th day of  the  experiment,  respectively. 
In the same way, Group D showed low level of creatinine 
(2.52 ± 0.025 mg/dl) on day 5 and high level (2.84 ± 
0.036 mg/dl) of creatinine on day 25 of the experiment. 
The observed low and high level of creatinine for Group 
E was 2.35 ± 0.070 and 2.70 ± 0.079 mg/dl at the 5th and 
25th day of the experiment, respectively. For Group F, 
the minimum creatinine level (2.06 ± 0.036 mg/dl) was 
recorded on day 5 and the maximum (2.59 ± 0.030 mg/dl) 
was recorded on day 25 of the experiment. Analysis of 
variance (ANOVA) of the creatinine level for all groups is 
shown in Table 4. The table showed that there was 
significant difference (P<0.05) in creatinine level in 
different groups and also at different days of analysis. 
Their combined effect (dose rate × different days of 
analysis) was also significant with a P value less than 
0.05. A graph has been plotted between the mean crea-





The uric acid level of all groups was analyzed at 0 day 
before medication, at 5, 15 and 25th day during 
medication, and at the 30th day of experiment (5th day of 
post medication). The mean ± SD of the obtained values 
of uric acid is shown in Table 6. For the un-medicated 
control group (G), the maximum value of uric acid was 
5.60 ± 0.010 µg/dl and the minimum was 5.59 ± 0.022 
µg/dl. The uppermost level of uric acid for Group  A was 
7.12 ± 0.005 µg/dl at the 25th day of the experiment, 
while the lowest level was 6.02 ± 0.013 µg/dl at the 5th 
day of the experiment. Similarly, the maximum level of 
uric acid for Group B was 8.93 ± 0.021 µg/dl and the 
minimum was 7.12 ± 0.013 µg/dl at the 25th and 5th day 
of the experiment, respectively. The peak level of uric 
acid for Group C was recorded on day 25 (11.94 ± 0.015 
µg/dl), while the lowest level was found on day 5 of the 
experiment (10.53 ± 0.371 µg/dl). Group D also showed 
high level of uric acid on day 25 (11.07 ± 0.024 µg/dl) and 
low level on day 5 of the experiment (9.67 ± 0.057 µg/dl), 
as shown in Table 3. However, Group E showed high 
level of uric acid on the 25th day of the experiment and 
the obtained value  was  10.59  ±  0.013  µg/dl,  while  the  




Table 3. The plasma uric acid level (mean ± SD) of various groups after administration of lead acetate at different dosage levels. 
 
Groups Dose rate 0 day (µg/dl) 5th day (µg/dl) 15th day (µg/dl) 25th (µg/dl) 30th day* (µg/dl) 
A 80 5.58 ± 0.006 6.02 ± 0.013 6.97 ± 0.033 7.12 ±0.005 6.96 ± 0.072 
B 120 5.58 ± 0.009 7.12 ± 0.013 7.97 ± 0.029 8.93 ±0.021 8.15 ± 0.021 
C 160 5.57 ± 0.010 10.53 ± 0.371 11.31 ± 0.008 11.94 ±0.015 11.00 ± 0.010 
D 200 5.58 ± 0.008 9.67 ± 0.057 10.53 ± 0.010 11.07 ±0.024 10.12 ± 0.006 
E 240 5.58 ± 0.006 9.16 ± 0.491 10.02 ± 0.033 10.59 ±0.013 10.03 ± 0.049 
F 280 5.58 ± 0.010 8.03 ± 0.029 9.27 ± 0.046 10.00 ±0.028 9.52 ± 0.022 
G Control 5.58 ± 0.008 5.59 ± 0.022 5.59 ± 0.013 5.59 ± 0.018 5.60 ± 0.010 
 















Dose rate* days 
(F-value) 
Sig.* 
GPT 10283159.663 1155453036.840 27170568.374 35395863.751 1875856.803 0.00 
Creatinine 677.062 251301.869 109.765 3703.531 314.475 0.00 
Uric acid 1660.773 803171.494 4579.927 5381.550 310.854 0.00 
 
*Sig = P value. P<0.05 = significant, P>0.05 = Non-significant, *The above observation shows that the DATA are significant not only from 






























Figure 1. Graph showing the plasma GPT level of the control group, as well 
as the groups medicated with lead acetate at different dosage levels. A = 
Lead acetate administered at the dose rate of 80 mg/kg; B = Lead acetate 
administered at the dose rate of 120 mg/kg; C = Lead acetate administered at 
the dose rate of 160 mg/kg; D = Lead acetate administered at the dose rate of 
200 mg/kg; E = Lead acetate administered at the dose rate of 240 mg/kg; F = 





lowest level of uric acid for the said group was observed 
on the 5th day of the experiment with a level of 9.16 ± 
0.491. For Group F, the maximum uric acid level (10.00 ± 
0.028 µg/dl) was recorded on day 25 and the minimum 
(8.03 ± 0.029 µg/dl) was on day 5 of the experiment 
(Table 3). 
Analysis of variance (ANOVA) of the uric acid level for  
all groups is shown in Table 4. Table 4 shows that there 
is a significant difference (P<0.05) in the uric acid level in 
different groups and also at different days of analysis. 
Their combined effect (dose rate × different days of 
analysis) was also significant with a P value less than 
0.05. However, a graph has been plotted between the 
mean uric acid  levels  of  different  groups,  as  shown  in  
































Figure 2. Graphical presentation of creatinine level during different days due 
to different lead acetate dose administered. A = Lead acetate administered at the 
dose rate of 80 mg/kg; B = Lead acetate administered at the dose rate of 120 
mg/kg; C = Lead acetate administered at the dose rate of 160 mg/kg; D = Lead 
acetate administered at the dose rate of 200 mg/kg; E = Lead acetate administered 
at the dose rate of 240 mg/kg; F = Lead acetate administered at the dose rate of 




Table 5. The post-mortem findings of dead chicks during the experiment. 
 
Group Dose (mg/kg b.wt) Liver Lungs Kidney Heart Brain Gizzard 
A 80 Pale Normal Swollen Normal Normal Normal 
B 120 Pale Congested Swollen Normal Normal Normal 
C 160 Pale Congested Swollen Swollen Congested Normal 
D 200 Pale Congested Swollen Swollen Normal Normal 
E 240 Pale Congested Swollen Swollen Normal Normal 
F 280 Pale Congested Swollen Swollen and dark in color Normal Normal 









The postmortem of dead chicks were performed to study 
the effect of lead acetate on liver, kidney, lungs, heart, 
brain and gizzard (Table 5). One chick from Groups A, B, 
C and D, and three from E and F died during the entire 
period of the experiment. 
 
 
Estimation of mortality rate 
 
The mortality rate for each group was estimated in 
percentage, using the following formula. 
 
       No. of dead chicks                   ×    100 
    Total no of experimental chicks  
Mortality rate in various groups 
 
The mortility rate was 0% in Groups A and G, 20% in 
Groups B, C and D and 60% in Groups E and F. 
 
 
Determination of lead concentration in organs 
 
The concentration of lead in various organs (brain, bone 
and liver) of the medicated Groups was determined using 
the atomic absorption spectroscopy at the department of 
Physics (Centralized Resource Laboratory), University of 
Peshawar. In the case of the bone, Group C presented 
the minimum concentration of lead with a mean ± SD 
value of 5.750 ± 0.957 g/g, while Group F presented the 
maximum concentration with a mean ± SD value of 30.75 
± 0.957 g/g (Table 6). In the case of the brain, the 
minimum Pb concentration was found in Group B (3.275 
± 0.96 g/g)  and  the  maximum  was   found   in   Group   








A B C D E F G 
Bone 7.250 ± 0.500 12 ± 0.816 5.750 ± 0.957 14.50 ± 1.291 21.00 ± 0.816 30.75 ± 0.957 1.250 ± 0.500 
Brain 3.80 ± 0.082 3.275 ± 0.96 2.400 ± 0.294 0.053 ± 0.013 7.675 ± 0.150 1.362 ± 0.038 0.200 ± 0.141 
































Figure 3. Graph showing the plasma uric acid level of different groups at different 
days. A = Lead acetate administered at the dose rate of 80 mg/kg; B = Lead acetate 
administered at the dose rate of 120 mg/kg; C = Lead acetate administered at the dose 
rate of 160 mg/kg; D = Lead acetate administered at the dose rate of 200 mg/kg; E = 
Lead acetate administered at the dose rate of 240 mg/kg; F = Lead acetate administered 




(7.675 ± 0.038 g/g). After the analysis of the samples of 
liver, Group A showed the minimum level of lead (0.018 ± 
0.01 g/g), while Group F showed the maximum level of 
lead (2.395 ± 0.013 g/g). The control group (G) has a 
mean ± SD value of 1.250 ± 0.500 g/g of lead acetate in 
bones, while it has 0.200 ± 0.141 and 0.012 ± 0.005 g/g 
in the brain and liver, respectively. However, a graph has 
been plotted between the mean concentrations of lead 
and different medicated and control groups (Figure 4). 
From the present results, it has been shown that lead 
accumulates in bones at high extent than in the brain, 
while the least quantity was determined in the liver. 
Therefore, it has been observed that lead has the 





Heavy metals become toxic when they are not 
metabolized by the body and accumulated in the soft 
tissues. Heavy metals may enter into the human body 
through   food,  water,  air,  or  absorption,  or  may  occur  
through the skin when they come in contact with humans 
in agriculture (Roberts, 1999). Like other lead 
compounds, lead acetate is very toxic. This study was 
undertaken to investigate the effect of lead acetate on 
GPT, creatinine and uric acid in broiler chicks. For this 
purpose, the broiler chicks were reared and intoxicated 
with lead acetate. Blood samples were collected and 
analyzed for blood biochemical parameters (GPT, 
creatinine and uric acid). 
 
 
Glutamate pyruvate transaminase level (GPT) 
 
The level of GPT is generally increased in situations 
where there is damage to the liver cell membrane. All 
types of liver inflammation can cause increase in GPT 
(Cobot, 2006). Rapid increases in GPT may indicate an 
acute process, while slow increase may be due to bile 
duct obstruction. Cell damage causes elevations of 
serum/plasma GPT due to leakage. The elevation of 
serum/plasma GPT correlates with the number of cells 
that  is  damaged. Falling  levels  of  GPT  may  indicate 






























Figure 4. Amount of lead estimated in various tissues of the treated chicks groups. A = Lead acetate 
administered at the dose rate of 80 mg/kg; B = Lead acetate administered at the dose rate of 120 mg/kg; C = 
Lead acetate administered at the dose rate of 160 mg/kg; D = Lead acetate administered at the dose rate of 
200 mg/kg; E = Lead acetate administered at the dose rate of 240 mg/kg; F= Lead acetate administered at the 




recovery (Fleming, 2006). GPT is more important in the 
diagnosis of heart and liver damage, which causes heart 
attack during toxicity or infection (David and Michael, 
2000). Plasma GPT in various Groups (A, B, C, D, E, F 
and G) was determined during and after treatment. The 
maximum and minimum value of GPT for the un-treated 
control Group (G) was 10.62 ± 0.010 and 10.61 ± 0.008 
IU/l, respectively, which was the lowest when compared 
with other medicated groups. This has been supported by 
Tatjana et al. (2005). 
In the present study, various dosage levels of lead 
acetate were administered, which led to the increase in 
GPT. Al-Wabel et al. (2007) has reported the same 
results in rats, which have also been treated with lead 
acetate and it showed that the level of GPT increased 
from an average of 23.0 to 37.3 IU/L. Same results have 
also been found by Ashmawy et al. (2005), who 
mentioned that lead acetate has a toxic effect on liver 
and increased the level of GPT. Similar results have also 
been published by Hayashi et al. (2005). They found that, 
lead acetate increased the serum GPT level. Also, similar 
results have been mentioned by many researchers 
(Shalan et al., 2005; Sokkary et al., 2005; Tatjana et al., 
2005). Swaran et al. (1987) repeated that lead acetate 





Creatinine is the breakdown product of creatine, which is 
an important part of the muscle. The test is performed to 
evaluate the  kidney  function.  If  the  kidney  function  is  
abnormal, the creatinine level will increase in the blood, 
due to decreased excretion of creatinine in the urine 
(Nissl and Terra, 2004; Hecht, 2006). Serum/plasma 
creatinine is a more sensitive indicator of renal function 
than the blood urea nitrogen (June and Juanita, 2004). 
The presence of the increased level of urea and 
creatinine concentration in the blood suggests the 
inability of the kidney to excrete these products (Overu et 
al., 2004). The creatinine values for all groups showed 
that kidney had been affected during lead acetate 
administration. As the dose increased, the creatinine 
level also increased. In some cases (Group C), the effect 
was higher as compared to the high dose administrated 
groups (D, E and F). It was observed that when its 
administration was stopped, creatinine level tended to de-
crease. Plasma creatinine in various groups (A, B, C, D, 
E, F and G) was determined during and after medication. 
The maximum and minimum values of creatinine for the 
non-treated control group (G) were 1.28 ± 0.033 and 1.26 
± 0.025 IU/l, respectively, which was the lowest as 
compared to other treated groups. 
The present results have been supported by Khalil-
Manesh et al. (1992), who mentioned that lead acetate 
increased serum creatinine level as compared to the 
control group, where rats were intoxicated. The normal 
creatinine level in rabbits, reported by Guignard and 
Drukker (1999), was also in agreement with the present 
results. In the present study, various dosage levels of 
lead acetate were administered, which led to the increase 
in creatinine as described in the results. Same results 
have been found by Abd El Rahiem et al. (2007), who 





in lead acetate treated rats. Similar results have been 
reported by many researchers (Abdel-Razik et al., 2007; 





Uric acid is a white, odourless, tasteless crystalline 
organic compound of carbon, nitrogen, oxygen and 
hydrogen. It is made in the liver and excreted by the 
kidney. Uric acid is a waste product that results from the 
break down of purine, which is a nucleic acid. If the liver 
produces too much uric acid, the patient will have too 
much of it in the blood. Uric acid is a weak organic acid 
that is barely soluble in water and insoluble in alcohol and 
ether (Encyclopedia, 2006). The uric acid test is used to 
determine the break down of the body cells. The test is 
also used to monitor the uric acid level when a patient 
has taken chemotherapy or radiation treatment (Lab Test 
Online, 2003). The present study showed that lead 
acetate affected the level of uric acid. As the dose 
increased, the uric acid level also increased. In some 
groups, the effect was higher (that is, Group C) as 
compared to other high dose medicated groups (that is, 
D, E and F). After the cessation of lead acetate 
administration, uric acid tended to decrease. In the 
present study, uric acid levels in various groups (A, B, C, 
D, E, F and G) were determined during and after 
medication. For the un-medicated control group (G), the 
maximum value of uric acid was 5.60 ± 0.010 µg/dl and 
the minimum was 5.59 ± 0.022 µg/dl. 
In the present study, various dosage levels of lead ace-
tate were administered, which led to the increase in uric 
acid as described in the results of the study. However, 
same results have been found by Abd El Rahiem et al. 
(2007) in rats, and have also been reported by Dioka et 
al. (2004), who mentioned that exposure of human 
subjects to lead in petrol increased the concentrations of 






In the un-medicated control (group G), no mortality was 
recorded. There was no mortality in the groups 
medicated with lead acetate at the dose rate of 80 mg/kg 
b.wt (Group A). A total of nine broiler chicks died during 
the entire experimental period (One from Groups B, C 
and D, and three from Groups E and F). The mortality 
rates observed for dosage levels of lead acetate at 120 
mg/kg (Group B), 160 mg/kg (Group C) and 200 mg /kg 
(Group D) were 20% for Groups E and F medicated at 
the dose rate of 240, while the mortality rates at 280 
mg/kg were 60%. So, it has been concluded that as the 
dose rate increased, the mortality rate also increased, 
although the postmortem findings of the control group (G) 
were normal. After  performing  the  post-mortem  for  the  




medicated groups, the gross pathological findings were: 
pale liver, lungs normal at the dosage level of 80 mg/kg 
but congested at higher doses, swollen kidney, heart 
normal at low doses but swollen at higher doses, and 
gizzard normal. Chow et al. (2006) recognized chronic 
lead exposure as a potential cause of kidney damage. 
Similar findings have been reported by other workers 




Concentration of lead in different organs 
 
In the un-medicated control group, the level of lead was 
at the lowest concentration as compared to the 
intoxicated groups, described in the results. In the 
present study, the accumulation pattern of lead in 
different organs was: bone> brain > liver. Same results 
have been found by Taggart et al. (2006), who mentioned 
that lead is accumulated in the bone in greater amount 
than in the liver. Lopez et al. (2000) have also reported 
the same results. Similarly, Kalisinska and Szuberla 
(1996), in males (n = 34) and females (n = 23) of long-
tailed duck, have also found same results, by mentioning 
that lead accumulates more in the brain. Furthermore, 






From the present study, it has been observed that lead 
acetate alters the plasma GPT, creatinine and uric acid 
level in broiler chickens by affecting the liver and kidney 
function. The toxic signs were much more prominent 
when high doses (240 and 280 mg/Kg b.wt) were 
administered. There was no pronounced toxicity present 
when low doses of lead acetate were used. After 
postmortem examination, it was found that internal 
organs, such as liver, lungs, kidney, brain and heart were 
severely affected at high doses as compared to low 
doses of lead acetate. However, the presence of lead in 
different organs indicated that the different organs have 
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